Literature DB >> 9010009

The prognosis and main prognostic indicators of Guillain-Barré syndrome. A multicentre prospective study of 297 patients. The Italian Guillain-Barré Study Group.

.   

Abstract

To assess the prognosis of the Guillain-Barré syndrome and identify the main prognostic indicators, 297 patients with Guillain-Barré syndrome recruited through a network of Italian centres were followed up for 24 months or until clinical recovery, whichever was earliest. For each patient the time to plateau, improvement, clinical recovery, or death was calculated, and prognostic indicators (age, sex, antecedent events, disability at admission and nadir, electrophysiological patterns) and treatments were noted. The mean duration of follow-up was 309 days. During this period, 212 patients (71%) recovered, 48 (16%) had residua and 33 (11%) died. The mean times to nadir, improvement and clinical recovery were 12, 28 and 200 days. Using life-tables and survival curves, the cumulative probability of achieving the plateau of symptoms was 73% by 1 week and 98% by 4 weeks. Improvement started during the first week in 36% of cases and within 4 weeks in 85%. The rates of clinical recovery at 1 and 4 weeks, 6, 12 and 24 months were 4, 24, 57, 70 and 82%, respectively. The chance of recovery was significantly affected by age, antecedent gastroenteritis, disability, electrophysiological signs of axonopathy, latency to nadir and duration of active disease. The main treatments did not seem to affect the chance of recovery.

Entities:  

Mesh:

Year:  1996        PMID: 9010009

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  32 in total

1.  Detection of serious bradyarrhythmias in Guillain-Barré syndrome: sensitivity and specificity of the 24-hour heart rate power spectrum.

Authors:  P Flachenecker; K Lem; W Müllges; K Reiners
Journal:  Clin Auton Res       Date:  2000-08       Impact factor: 4.435

2.  Serial electrophysiological findings in Guillain-Barré syndrome not fulfilling AIDP or AMAN criteria.

Authors:  Takafumi Hosokawa; Hideto Nakajima; Kiichi Unoda; Kazushi Yamane; Yoshimitsu Doi; Shimon Ishida; Fumiharu Kimura; Toshiaki Hanafusa
Journal:  J Neurol       Date:  2016-06-08       Impact factor: 4.849

Review 3.  Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis.

Authors:  Bianca van den Berg; Christa Walgaard; Judith Drenthen; Christiaan Fokke; Bart C Jacobs; Pieter A van Doorn
Journal:  Nat Rev Neurol       Date:  2014-07-15       Impact factor: 42.937

4.  Clinical presentations as predictors of prolonged mechanical ventilation in Guillain-Barré syndrome in an institution with limited medical resources.

Authors:  Umarudee Toamad; Chanon Kongkamol; Suwanna Setthawatcharawanich; Kitti Limapichat; Kanitpong Phabphal; Pornchai Sathirapanya
Journal:  Singapore Med J       Date:  2015-10       Impact factor: 1.858

Review 5.  Acute lung failure.

Authors:  Rob Mac Sweeney; Daniel F McAuley; Michael A Matthay
Journal:  Semin Respir Crit Care Med       Date:  2011-10-11       Impact factor: 3.119

Review 6.  Clinical applications of intravenous immunoglobulins in neurology.

Authors:  R A C Hughes; M C Dalakas; D R Cornblath; N Latov; M E Weksler; N Relkin
Journal:  Clin Exp Immunol       Date:  2009-12       Impact factor: 4.330

7.  Muscle MRI in severe Guillain-Barré syndrome with motor nerve inexcitability.

Authors:  María J Sedano; Ana Canga; Carmen de Pablos; José M Polo; José Berciano
Journal:  J Neurol       Date:  2013-01-31       Impact factor: 4.849

8.  Outcome in childhood Guillain-Barré syndrome.

Authors:  Veena Kalra; Naveen Sankhyan; Suvasini Sharma; Sheffali Gulati; Rama Choudhry; Benu Dhawan
Journal:  Indian J Pediatr       Date:  2009-04-16       Impact factor: 1.967

9.  An electrophysiological classification associated with Guillain-Barré syndrome outcomes.

Authors:  Takafumi Hosokawa; Hideto Nakajima; Kiichi Unoda; Kazushi Yamane; Yoshimitsu Doi; Shimon Ishida; Fumiharu Kimura; Toshiaki Hanafusa
Journal:  J Neurol       Date:  2014-08-01       Impact factor: 4.849

10.  Painful peripheral neuropathies.

Authors:  P Marchettini; M Lacerenza; E Mauri; C Marangoni
Journal:  Curr Neuropharmacol       Date:  2006-07       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.